{
  "docId": "019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "docSlug": "714b2223d61a474cc0c3d011e3fc18ab",
  "documentTitle": "Centessa | IPO Presentation Deck | 33 slides",
  "authorId": "centessa",
  "authorName": "Centessa Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 22,
  "pageCount": 33,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to summarize mission, data, and market.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ff46-75e9-a6a2-27d0e899d3b8/22",
  "deckHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "deckJsonHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8.json",
  "deckAnchorHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.68,
        "y": 0.45
      },
      "kind": "list",
      "text": "Market opportunity: Estimated prevalence of 200,000 PiZZ individuals worldwide. PiMZ prevalence of 42.4 million individuals and observed in large subset of COPD and NASH populations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3aa69976-b949-4da3-adc3-fd491a905d6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Mission: Develop a potent and specific catalytic folding corrector of Z-A1AT to increase serum levels and reduce liver burden to treat liver and lung disease manifestations of A1AT deficiency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a929bf23-6025-49bf-8bab-bdb3da898875",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.45
      },
      "kind": "list",
      "text": "De-risking data: ZF874 increased levels of active Z-A1AT in the blood and improved markers of liver pathology in PiZ mice. Seven cohorts of healthy volunteers successfully dosed up to 50mg/kg of ZF874 with excellent oral bioavailability and all doses well tolerated except for transient apparent Cmax effect at 50mg/kg in fasted state",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2287d23-8424-4571-97a3-26e552d8afc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Developing Phase 1 and preclinical stage folding correctors for Z-variant of alpha-1-antitrypsin (A1AT), to treat both liver and lung disease manifestations of A1AT deficiency",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0f6cf86-8da4-4eca-9db5-fb1f244ebd78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Z Factor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9889613-74e7-4673-b100-3d834f43608d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "7c5ad024-478b-4b7e-8913-c53cd5874a7d",
      "evidence": "This slide provides a high-level overview of the Z Factor program, including its mission, market opportunity, and approach.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}